Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer Clinical Trial

Official title:

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05721651
• Other study ID #: HMPL-013-E2-GC-102
• Status: Recruiting
• Phase: Phase 2
• Start date: April 2023
• Est. completion date: March 2026

Study information

• Verified date: April 2023
• Source: The First People's Hospital of Changzhou
• Contact: wu jun
• Phone: 13057144311
• Email: wujun68[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Maintenance therapy is very important in advanced HER-2 negative gastric cancer, and immune monotherapy has no obvious benefit in the first-line maintenance treatment of advanced gastric cancer； Fruquintinib is a potent small-molecule VEGFR inhibitor with high kinase selectivity；Studies have shown that immunotherapy combined with antiangiogenic agents is promising for synergistic antitumor effects； The aim of this study was to observe and evaluate the efficacy and safety of Fruquintinib combined with PD-1 inhibitor in the first-line maintenance treatment of advanced HER-2 negative gastric cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 2026
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 years old, regardless of gender, volunteer to participate in the trial and sign informed consent;

2. Advanced gastric adenocarcinoma confirmed by pathology (including gastroesophageal junction adenocarcinoma) with extragastric measurable lesions (RECIST 1.1 criteria);

3. Advanced HER-2-negative gastric cancer patients who received first-line PD-1 inhibitors (nivolumab/sindilizumab/tirelizumab) combined with standard chemotherapy and were assessed as non-PD according to RECIST 1.1 criteria;Chemotherapy regimen: SOX/FOLFOX/CAPEOX or fluorouracil combined with purple shirt;Patients receiving single-agent chemotherapy were allowed to enroll;Chemotherapy regimens are used for 4-8 cycles;

4. ECOG score: 0-1;

5. Expect to survive for at least 3 months;

6. Major organ function within 7 days before treatment meets the following criteria: (1) hemoglobin (HB) =90 g/L; (2) Absolute neutrophil ANC =1.5×109/L; (3) Platelet (PLT) =100×109/L;

7. Biochemical tests should meet the following criteria: (1) Total bilirubin (TBIL) =1.5 times the upper limit of normal value (ULN), or =2.5 times the upper limit of normal value (ULN) in the case of liver metastasis (2) alanine aminotransferase (ALT) and aspartate aminotransferase AST=2.5 ×ULN, if accompanied by liver metastasis, ALT and AST=5×ULN(3) Serum creatinine (Cr) =1.5×ULN or creatinine clearance (CCr)=60ml/min;

8. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) = the lower limit of normal (50%);

9. Patients of childbearing age (including female and female partners of male patients) must take effective birth control measures

10. he subjects volunteered to participate in this study and signed the ICF;

11. Good compliance is expected, and the efficacy and adverse reactions can be followed up according to the protocol requirements.

Exclusion Criteria:

1. Previous use of antiangiogenic drugs, such as bevacizumab, apatinib, anlotinib, lenvatinib and other antiangiogenic drugs

2. Previous treatment with more than one immune checkpoint inhibitor;

3. Patients who had previously interrupted treatment due to immune-related toxicity during immunotherapy;

4. Patients with severe history of allergy or allergic constitution;

5. Pregnant or lactating women;

6. Patients who have participated in other clinical trials and have not terminated the trial;

7. Patients with a definite propensity for gastrointestinal bleeding. Including the following conditions: ? local active ulcer lesions, and stool occult blood 2+ or abovePatients with fecal occult blood 2+ allowed to retest fecal occult blood and determined by the investigator to have a clear benefit could be enrolled) ? Patients with melena and hematemesis within 3 months; ? Gastroscopy is required for patients with fecal occult blood 1+ and primary gastric tumor that has not been surgically resected, such as ulcerated gastric cancer, and major gastrointestinal bleeding may occur according to the main investigator of the center;

8. Patients with any severe and/or uncontrolled disease, including: (1) patients with poorly controlled blood pressure (systolic blood pressure =150 mmHg, diastolic blood pressure =100 mmHg); (2) Patients with grade I or higher myocardial ischemia or infarction, arrhythmias (including QTc = 480ms), or congestive heart failure grade 2 (New York Heart Association (NYHA) classification); (3) Active or uncontrolled severe infection (=CTC AE grade 2 infection); (4) Liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need antiviral therapy; (5) Renal failure requiring hemodialysis or peritoneal dialysis; (6) Have a history of immunodeficiency, including being HIV positive or suffering from other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation; (7) Two consecutive routine urine tests indicated urinary protein =++, and confirmed 24-hour urinary protein quantity > 1.0 g; (8) suffer from mental illness, including epilepsy, dementia, severe depression, mania, etc

9. Receiving major surgical treatment, open biopsy or obvious traumatic injury within 28 days before grouping (body-body clinical evaluation)

10. Any history of active autoimmune disease or autoimmune disease, including but not limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis, pituitary inflammation, vasculitis, systemic lupus erythematosus, etc.

11. Patients whose imaging showed that the tumor had invaded the periphery of important blood vessels or who were judged by the investigator to be highly likely to invade important blood vessels during the subsequent study and cause fatal massive bleeding;

12. Patients with any evidence of bleeding constitution or history, regardless of severity;Patients who had any bleeding or bleeding events =CTCAE grade 3 in the 4 weeks before enrollment had unhealed wounds, ulcers, or fractures;

13. 6 months have experienced an arteriovenous thrombotic event, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism;

14. Patients with brain metastases associated with symptoms or symptom control for less than 2 months;

15. Persons with a history of psychotropic drug abuse and inability to abstain or mental disorders;

16. Subjects with dysphagia or known drug absorption disorders;

17. Other conditions deemed inappropriate for inclusion by the investigator?

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Fruquintinib+PD-1
This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib(4mg orally, once daily for 3 wks on/1 wk off )combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first. PD-1: Nivolumab(360mg IV d1, Q3W);Sintilimab(200mg IV d1, Q3W);Tislelizumab(200mg IV d1, Q3W) can be selected;

Locations

Country	Name	City	State
China	The First People's Hospital of Changzhou	Changzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Wu Jun

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival (PFS)	Tumor assessment will be performed using radiography method every 8 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1	from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Secondary	Overall survival (OS)	Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1	from randomization until death due to any cause, assessed up to 3 year
Secondary	Objective response rate (ORR)	Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1	from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Secondary	Disease control rate (DCR)	Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1	from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Secondary	Safety and tolerance evaluated by incidence, severity and outcomes of AEs	Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 5.0	from first dose to 30 days post the last dose